Gilead Sciences, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.11B | $30.39B | $32.64B | $24.89B | $11.20B | $9.70B | $8.39B | $7.95B |
| Cost of Revenue | $4.37B | $4.26B | $4.01B | $3.79B | $2.86B | $2.47B | $2.12B | $1.87B |
| Gross Profit | $21.74B | $26.13B | $28.63B | $21.10B | $8.34B | $7.23B | $6.26B | $6.08B |
| Gross Margin | 83.3% | 86.0% | 87.7% | 84.8% | 74.5% | 74.5% | 74.7% | 76.5% |
| Operating Expenses | ||||||||
| Research & Development | $3.73B | $5.10B | $3.01B | $2.85B | $2.12B | $1.76B | $1.23B | — |
| SG&A Expense | $3.88B | $3.40B | $3.43B | $2.98B | $1.70B | $1.46B | $1.24B | $1.04B |
| Operating Income | $14.12B | $17.63B | $22.19B | $15.27B | $4.52B | $4.01B | $3.79B | $3.96B |
| Operating Margin | 54.1% | 58.0% | 68.0% | 61.3% | 40.4% | 41.3% | 45.2% | 49.8% |
| Interest Expense | $1.12B | $964.0M | $688.0M | $412.0M | $307.0M | $361.0M | $205.4M | $109.0M |
| Pretax Income | $13.53B | $17.10B | $21.66B | $14.86B | $4.21B | $3.61B | $3.65B | $3.91B |
| Income Tax Expense | $8.89B | $3.61B | $3.55B | $2.80B | $1.15B | $1.04B | $861.9M | $1.02B |
| Net Income | $4.63B | $13.50B | $18.11B | $12.10B | $3.08B | $2.59B | $2.80B | $2.90B |
| Net Margin | 17.7% | 44.4% | 55.5% | 48.6% | 27.5% | 26.7% | 33.4% | 36.5% |
| EPS (Basic) | $3.54 | $10.08 | $12.37 | $7.95 | $2.01 | $1.71 | $1.81 | $1.69 |
| EPS (Diluted) | $3.51 | $9.94 | $11.91 | $7.35 | $1.81 | $1.64 | $1.77 | $1.66 |
| Shares Outstanding (Basic) | 1.31B | 1.34B | 1.46B | 1.52B | 1.53B | 1.52B | 1.55B | 1.71B |
| Shares Outstanding (Diluted) | 1.32B | 1.36B | 1.52B | 1.65B | 1.70B | 1.58B | 1.58B | 1.75B |
| Dividends Per Share | $2.08 | $1.84 | $1.29 | $0.00 | $0.00 | — | — | — |